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There’s an old saying in Washington
DC — making laws is like making
sausage; you’re better off not
knowing the details. Well, that same
spirit often applies to the coverage of
science news. The focus is on the
succulent final product rather than
the process required to get there. But
science journalists have found the
need to take a break from that
approach with one big biology story:
the tale of angiostatin and endostatin.
The fate of this story was cast last
May, when the New York Times all but
declared that victory against cancer
was just a few years away, thanks to
Harvard’s Judah Folkman and his
amazing molecules (see Mediawatch,
Curr Biol 1998, 8:R438). Angiostatin
and endostatin together had
eradicated tumors in mice by cutting
off their blood supply; humans,
seemingly, would be next.
This, of course, had vast
implications not only for human
health but for the companies
(EntreMed and Bristol-Myers
Squibb) and shareholders with a
stake in these potential drugs. So
last November, a reporter from the
Wall Street Journal checked up on the
progress and made a rather startling
discovery: Scientists at the National
Cancer Institute had been unable to
reproduce Folkman’s results. Simply
reporting that result, though, could
suggest either that Folkman was a
charlatan, or that the NCI scientists
were all thumbs in the lab.
Of course, neither of those is the
case. So the Journal article dug into
the process of science, explaining
the need for reproducibility and the
trouble, sometimes, of attaining it.
The stuff, it turns out, is hard to
make, hard to transport, and hard to
handle. “Says [Bristol-Myers
Squibb] senior vice president of
pharmaceutical development,
Christopher Cimarusti: ‘There’s a
difference between a lab curiosity
and something you can take forward
in man’. That distinction, while
eminently clear to scientists such as
Dr Folkman, is often lost in the
public’s understanding of the
immensely complicated quest for a
cancer cure.”
Genentech scientists also tried
and failed to reproduce Folkman’s
published results. The New York
Times interviewed Arthur Levinson,
the chief executive of Genentech, for
a story that appeared one day after
the Journal’s. “If we’re doing
something wrong, I would like to
know what it is, because we’re all
hoping he’s right,” Dr Levinson said.
“But things like this shouldn’t
languish too long, because the whole
basis of science is reproducibility. If
they can’t be reproduced, at some
point you have to ask yourself, are
the initial claims correct?”
Failing, getting stuck and plain
being wrong happen in science all
the time
By February, the suspense was too
much. Again the Wall Street Journal,
following the bouncing dollar,
reported that Bristol-Myers, which
has the rights to develop angiostatin,
was shelving the product for the time
being. An official at EntreMed, a
small biotech company which also
has an interest in angiostatin and
endostatin (see Gazetteer, Curr Biol
1998, 8:R633), tried to convince the
New York Times that the Bristol-Myers
announcement was a “non-event”.
But investors didn’t buy that; the
price of an EntreMed share dropped
47% in a single day.
Folkman himself by and large has
avoided the media. But in February,
a reporter from the Boston Herald sat
in on a talk he gave in Boston.
“Folkman said one reason other labs,
including NCI, have had problems
reproducing his work is that it is
difficult to learn how to inject the
mice with the drug without killing
them. ‘It takes a lot of skill to not
lose a mouse,’ he said. ‘We spend a
lot of time teaching them how to do
it’.” One could argue whether this
comment helped resolve the
mystery, or simply added to it.
National Public Radio devoted an
entire story to the process of science,
using the angiostatin affair as a
stepping-off point. “Scientists have
learned to be skeptics,” reported
Alison Richards. “They know that
however convincing a new piece of
research is, problems will arise.
Failing, getting stuck and plain being
wrong happen in science all the time,
but you don’t usually hear about it,
unless, of course, you read the
science journals.”
The Boston Globe, in turn, broke
some encouraging news in
mid-February. NCI scientists,
working in Folkman’s lab, had finally
been able to reproduce his results.
“ ‘This substantiates the idea that
these are technical issues’ that
caused the initial failures of the drug
to work at the institute,” NCI’s
Robert Wittes told the Boston Globe.
“Now we will move to facilities in
Frederick and try to reproduce the
results down here.”
But while reporting that
EntreMed’s stock value doubled on
that news, the Wall Street Journal
didn’t breathe a final sigh of relief.
“Independent confirmation of
Folkman would be very exciting;
however, these results don’t qualify as
such,” George Yancopoulos, chief
scientific officer at Regeneron
Pharmaceuticals, told the Journal.
“What worries me is that several years
after the discovery of endostatin,
there is still no explanation for how it
works. It’s still black magic.” Wittes at
the NCI added his note of caution:
“We have to make sure it’s
synthesizable outside Boston.”
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